Aspirin in primary prevention of cardiovascular disease in diabetes

It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Papazafiropoulou, Athanasia K., Melidonis, Andreas, Antonopoulos, Stavros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487832/
https://www.ncbi.nlm.nih.gov/pubmed/36161214
http://dx.doi.org/10.5114/amsad.2021.105596
_version_ 1784792527879012352
author Papazafiropoulou, Athanasia K.
Melidonis, Andreas
Antonopoulos, Stavros
author_facet Papazafiropoulou, Athanasia K.
Melidonis, Andreas
Antonopoulos, Stavros
author_sort Papazafiropoulou, Athanasia K.
collection PubMed
description It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabetes, after the results of major clinical trials and meta-analyses, is unclear. The observed discrepancies might be explained in part in terms of the differences between the background cardiovascular risks, follow-up periods, age and gender of the study populations. Recently, the results of the ASCEND trial in people with diabetes documented the cardiovascular benefit of aspirin for primary prevention, but with an increased risk of bleeding that might outweigh the observed cardiovascular benefit. Therefore, current guidelines recommend its use for primary prevention in people with and without diabetes under specific circumstances. The purpose of the present review is to summarize the existing literature data regarding the place that aspirin has in primary prevention of cardiovascular disease in people with diabetes.
format Online
Article
Text
id pubmed-9487832
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-94878322022-09-22 Aspirin in primary prevention of cardiovascular disease in diabetes Papazafiropoulou, Athanasia K. Melidonis, Andreas Antonopoulos, Stavros Arch Med Sci Atheroscler Dis State of the Art Paper It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabetes, after the results of major clinical trials and meta-analyses, is unclear. The observed discrepancies might be explained in part in terms of the differences between the background cardiovascular risks, follow-up periods, age and gender of the study populations. Recently, the results of the ASCEND trial in people with diabetes documented the cardiovascular benefit of aspirin for primary prevention, but with an increased risk of bleeding that might outweigh the observed cardiovascular benefit. Therefore, current guidelines recommend its use for primary prevention in people with and without diabetes under specific circumstances. The purpose of the present review is to summarize the existing literature data regarding the place that aspirin has in primary prevention of cardiovascular disease in people with diabetes. Termedia Publishing House 2021-04-22 /pmc/articles/PMC9487832/ /pubmed/36161214 http://dx.doi.org/10.5114/amsad.2021.105596 Text en Copyright: © 2021 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle State of the Art Paper
Papazafiropoulou, Athanasia K.
Melidonis, Andreas
Antonopoulos, Stavros
Aspirin in primary prevention of cardiovascular disease in diabetes
title Aspirin in primary prevention of cardiovascular disease in diabetes
title_full Aspirin in primary prevention of cardiovascular disease in diabetes
title_fullStr Aspirin in primary prevention of cardiovascular disease in diabetes
title_full_unstemmed Aspirin in primary prevention of cardiovascular disease in diabetes
title_short Aspirin in primary prevention of cardiovascular disease in diabetes
title_sort aspirin in primary prevention of cardiovascular disease in diabetes
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487832/
https://www.ncbi.nlm.nih.gov/pubmed/36161214
http://dx.doi.org/10.5114/amsad.2021.105596
work_keys_str_mv AT papazafiropoulouathanasiak aspirininprimarypreventionofcardiovasculardiseaseindiabetes
AT melidonisandreas aspirininprimarypreventionofcardiovasculardiseaseindiabetes
AT antonopoulosstavros aspirininprimarypreventionofcardiovasculardiseaseindiabetes